Filing Details

Accession Number:
0001104659-20-069570
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-03 20:20:13
Reporting Period:
2020-06-01
Accepted Time:
2020-06-03 20:20:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1659323 Iterum Therapeutics Plc ITRM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1202793 Michael Powell C/o Sofinnova Investments, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
1245624 James Healy C/o Sofinnova Investments, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
1612133 Sofinnova Venture Partners Ix, L.p. C/o Sofinnova Investments, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
1612134 Sofinnova Management Ix, L.l.c. C/o Sofinnova Investments, Inc.
3000 Sand Hill Road, Bldg. 4, Suite 250
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2020-06-01 100,000 $1.69 1,626,514 No 4 S Direct
Ordinary Shares Disposition 2020-06-02 400,000 $1.61 1,226,514 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b).
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The securities are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.